Presidents of JSC AKRIKHIN and JSC Active Component Denis Chetverikov and Alexander Semenov signed a memorandum on deepening strategic partnership at the St. Petersburg International Economic Forum.
The agreement is aimed at developing joint work on localizing the full cycle of production of drugs for the treatment of cardiovascular and endocrine diseases.
Historically Russian pharmaceutical manufacturer Akrikhin JSC and the local pharmaceutical substance manufacturer JSC «Active Component» have collaborated in the antihistamine and dermatology segments. With the introduction of the localization strategy1, the companies began to deepen their collaboration to include fully localized molecules in AKRIKHIN’s cardiology and endocrinology portfolio.
Since 2021, the total volume of contracts between the two companies has increased 4-fold. Thanks to this partnership, the annual sales volume of Akrikhin’s fully localized products will exceed 6 billion rubles by 2030. In total, by 2030 — 25 billion rubles.
«Today we are expanding our cooperation to the level of strategic partnership and plan to introduce local substances at the earliest stages, starting with development, bioequivalence and clinical trials, if required. We have chosen cardiovascular diseases and diabetes as the main groups of nosologies for cooperation, in addition to those areas in which joint work is already underway».
said Denis Chetverikov, President of Akrikhin JSC.
President of JSC Active Component Alexander Semenov emphasized:
«Full-cycle production of socially significant drugs is the only way to achieve true import independence for our country. This is a strategic choice that Russian manufacturers are making. We see this as our mission. The production of drugs in Russia from the pharmaceutical substance to the finished drug will provide residents of our country with high-quality modern drugs.».
List of sources:
- According to the Pharma 2030 strategy, the share of key drugs produced in Russia using a full cycle should reach 80% by 2030